Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen

Technology appraisal guidance
Reference number: TA316
Published: 23 July 2014

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): FAD document

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): FAD document

Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): FAD document
09 May 2014
(248.96 Kb 12 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 06 May 2014